Standout Papers

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, ope... 2008 2026 2014 2020 843
  1. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study (2008)
    Daniel J. Drucker, John B. Buse et al. The Lancet

Immediate Impact

3 by Nobel laureates 13 from Science/Nature 114 standout
Sub-graph 1 of 17

Citing Papers

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
2025 Standout
Adipose tissue retains an epigenetic memory of obesity after weight loss
2024 StandoutNature
39 intermediate papers

Works of Michael Trautmann being referenced

Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study
2019
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
2008 Standout
and 21 more

Author Peers

Author Last Decade Papers Cites
Michael Trautmann 5843 2467 2648 83 7.0k
Odette Poirier 3397 1740 1627 115 9.1k
David M. Kendall 5141 2187 2917 105 7.2k
Baptist Gallwitz 4102 1891 2132 129 5.5k
Mark Fineman 7369 3234 3993 57 8.6k
Keith D. Kaufman 6074 2772 2069 118 9.0k
Åke Sjöholm 2178 2331 1803 157 5.9k
Ingrid Gause‐Nilsson 5914 2606 2401 68 7.3k
Axel Haupt 4007 1893 1684 107 5.9k
Greg Fulcher 7548 2847 3312 62 9.2k
M. Michael Wolfe 1394 1535 2901 136 6.8k

All Works

Loading papers...

Rankless by CCL
2026